Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Triethylamine | HCID 8471 | — |
| Reactant | 2-Morpholinoethanol | HCID 61163 | — |
| Reactant | O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate | HCID 2733207 | — |
| Reactant | HCID 59258281 | HCID 59258281 | — |
| Catalyst | Formic Acid | HCID 284 | — |
| Solvent | Dimethylformamide | HCID 6228 | — |
| Product | HCID 16734598 | HCID 16734598 | — |
Reaction Steps
A solution of 90 mg (0.13 mmol) (R)-2-(1′-carboxymethyl-4,4′-bipiperidinyl-1-yl)-1-(4-methyl-2-oxo-2,3-dihydro-benzoxazol-6-ylmethyl)-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate, 48 mg (0.15 mmol) TBTU and 26 μL (0.19 mmol) triethylamine in 1.4 mL DMF was stirred for 1 h at RT. Then 18 μL (0.15 mmol) 2-morpholin-4-yl-ethanol was added. The reaction mixture was stirred for 16 h at RT. 4 drops of formic acid were added, the mixture was filtered through a syringe filter and purified by HPLC. The fractions containing the product were combined, made alkaline with 5% NaHCO3 solution, extracted with 50 mL EtOAc and the organic phase was dried on Na2SO4. After the desiccant and solvent had been eliminated the residue was triturated with DIPE, suction filtered and dried.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US07625886B2 |
|---|
| Source dataset | uspto-grants-2009_12 |
|---|
| ORD ID | ord-ee449c4e99bd41d092ba35c628122b63 |
|---|
| Source note | uspto-grants-2009_12 |
|---|